儿童和青少年甲状腺功能亢进症的^(131)Ⅰ治疗  

^(131)I treatment of hyperthyroidism in children and adolescents

作　　者：赵德善[1] 孔繁振[2] 司宏伟[3] 朱亦堃[4] 

机构地区：[1]山西医科大学第一医院核医学科,太原030001 [2]军区解放军总医院核医学科 [3]中国医学科学院肿瘤医院核医学科 [4]山西医科大学第二医院内分泌科

出　　处：《中华内分泌代谢杂志》2006年第6期566-568,共3页Chinese Journal of Endocrinology and Metabolism

摘　　要：对适宜^(131)Ⅰ治疗的儿童和青少年甲亢患者进行治疗前后的疗效观察研究。临床确诊及对抗甲亢药物耐药或有禁忌证的31例患者接受了^(131)Ⅰ治疗。其中15例痊愈,11例明显好转,5例甲减；18例突眼患者中,8例突眼基本恢复正常,4例缓解,5例无变化和1例加重。对不宜行抗甲亢药物治疗的10岁以上甲亢患者来说,^(131)Ⅰ是一种相对安全、有效的治疗方法。The efficacy of ^131Ⅰ treatment of hyperthyroidism in children and adolescents was evaluated. Being unsuitable for medical therapy, 31 patients （aged 11-18 years） with hyperthyroidism received ^131Ⅰ treatment with a dose of 0. 925-3.33 MBq/g of thyroid and were followed-up for 20 to 76 months. Fifteen patients were euthyroid, 5 suffered from late-onset hypothyroidism, and 11 were still hyperthyroid, but their symptoms and signs of hyperthyroidism were markedly improved. Of the 18 patients with thyroid-associated ophthalmopathy （ TAO）, 8 patients recovered, 4 were improved, TAO in 1 patients deteriorated and in 5 patients remained unchanged. ^131Ⅰ is a relative safe and effective treatment for children and adolescents above 10 years old with hyperthyroidism, being unsuitable for medical therapy.

关 键 词：甲状腺功能亢进症 碘放射性同位素 治疗 随访研究 儿童和青少年 

分 类 号：R581.1[医药卫生—内分泌]